Fluoroquinolones: a review on anti-tubercular activity
Monatshefte fur Chemie, ISSN: 0026-9247, Vol: 152, Issue: 8, Page: 881-894
2021
- 4Citations
- 17Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Tuberculosis is among the most calamitous disease, leading to a high number of deaths worldwide. After the discovery of rifampicin, no new anti-tuberculosis drug has been introduced; however, USFDA approved bedaquiline and delamanid which are limited to the treatment of extensive drug resistance tuberculosis. Fluoroquinolones are already categorized as anti-tuberculosis drugs by the WHO, but Mycobacterium tuberculosis has developed resistance to fluoroquinolones. Due to the overwhelming nature of tuberculosis across the globe, urge the scientific community to develop molecules against Mycobacterium tuberculosis with improved affinity and efficacy. In this review article, we have tried to summarize the role, structure–activity relationship, and current developments of fluoroquinolone derivatives in the management of tuberculosis. The present review will provide better insights to work further in this area. Graphic abstract: [Figure not available: see fulltext.]
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85112038068&origin=inward; http://dx.doi.org/10.1007/s00706-021-02806-7; https://link.springer.com/10.1007/s00706-021-02806-7; https://link.springer.com/content/pdf/10.1007/s00706-021-02806-7.pdf; https://link.springer.com/article/10.1007/s00706-021-02806-7/fulltext.html; https://dx.doi.org/10.1007/s00706-021-02806-7; https://link.springer.com/article/10.1007/s00706-021-02806-7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know